Mandate

Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden

November 14, 2014

Vinge advised Nexstim on its IPO and dual listing of shares on First North Finland and First North Sweden. In the IPO, Nexstim issued 2,408,339 news shares at a subscription price of EUR 6.35 per share, amounting to gross proceeds of roughly EUR 15.3 million. Trading in the company's shares on First North Finland and First North Sweden commenced on 14 November 2014. The transaction is the first ever dual listing on the First North exchanges maintained by Nasdaq.

Nexstim is a medical technology company based in Finland that aims to improve rehabilitation for stroke patients. 

Vinge’s team primarily consisted of Jesper Schönbeck, Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025